Molluscum Contagiosum Treatment Market By Treatment Type (FDA-Approved Prescription Therapies, Physical Removal Procedures, Off-Label Topical Therapies, Supportive and Immune-Directed Treatments), By Administration Setting (Healthcare Provider-Administered Treatment, Home-Based Treatment), By Patient Group (Pediatric Patients, Adults, Immunocompromised Patients), By Distribution Channel (Dermatology and Pediatric Clinics, Hospital Outpatient Departments, Retail Pharmacies, Mail-Order Pharmacies, Patient-Support Services), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Molluscum Contagiosum Treatment Market: Prescription Approvals Create a Defined Dermatology Market

The Global Molluscum Contagiosum Treatment Market was valued at approximately USD 0.72 million in 2025 and is projected to reach approximately USD 1.32 million by 2032, expanding at a CAGR of 9.0% during 2026–2032, according to internal projections by Strategic Market Research.

 

Molluscum contagiosum often clears without treatment within six months to two years, making observation a common first approach. When faster clearance or reduced spread is preferred, dermatologists may use cryotherapy, curettage, cantharidin, prescription acids, or other topical therapies.

 

The market is moving from a largely procedure-based and off-label model toward regulated prescription treatment. The U.S. approvals of YCANTH in July 2023 and ZELSUVMI in January 2024 established two commercial channels. YCANTH is administered by healthcare professionals to patients aged two years and older, while ZELSUVMI is approved from one year of age and can be applied at home by patients or caregivers. YCANTH generates revenue through office administration, medical-benefit reimbursement, repeat visits, and applicator use. ZELSUVMI operates through prescriptions, pharmacy benefits, retail and mail-order distribution, and patient-support programmes.

 

Patient Volume Is Larger Than the Treated Market

Molluscum contagiosum primarily affects children between one and ten years of age. Published evidence places pediatric prevalence at approximately 5.1%–11.5%, while Verrica estimates that about six million people in the United States are affected, primarily children. The size of this clinical population is considerably larger than the actively treated population because many cases clear without intervention.

Spontaneous clearance remains the main commercial restraint. A prospective UK study reported an average resolution time of 13.3 months, while 30% of cases remained unresolved after 18 months and 13% persisted beyond two years. Families are more likely to seek treatment when lesions spread, cause itching or inflammation, affect visible or sensitive areas, worsen eczema, become infected, or create concern about transmission.

Immunocompromised patients can develop extensive or treatment-resistant disease and may require closer specialist management. The market therefore expands mainly by converting selected observed cases into active treatment rather than through changes in infection prevalence.

 

Procedures and Off-Label Topicals Remain Important Competitors

Cryotherapy and curettage remain established approaches for removing individual lesions. Their market value is captured through physician services, procedural reimbursement, follow-up visits, and local anaesthesia rather than through branded drug revenue. CDC guidance confirms that cryotherapy, curettage, and laser treatment require trained providers and can involve pain, local injury, or scarring.

Traditional topical approaches, including potassium hydroxide, tretinoin, prescription acids, salicylic acid combinations, podophyllotoxin, and compounded cantharidin, continue to compete on familiarity and lower acquisition cost. Their formulation consistency, age suitability, treatment duration, and reimbursement vary widely.

Imiquimod has also been used off-label, particularly in adults, but it has not demonstrated efficacy in children and is not recommended for pediatric molluscum contagiosum because adverse skin reactions can occur. Its role is therefore limited in the childhood population that forms the largest treatment segment.

These established alternatives place pricing pressure on branded therapies. Prescription products must offer clearer administration pathways, standardized dosing, predictable access, or improved convenience to justify treatment costs.

Cryotherapy can provide relatively rapid removal but is often difficult for younger children or patients with many lesions. Curettage offers direct removal but may require local anaesthesia and can generate repeat visits when new lesions appear. These characteristics preserve procedure revenue for specialists while creating demand for treatments that avoid lesion-by-lesion freezing or scraping.

The competitive pressure from these lower-cost alternatives is strongest in mild cases. Branded products gain relevance when the infection persists, spreads across multiple body areas, worsens associated eczema, or creates a treatment burden that families no longer consider acceptable.

 

YCANTH Builds a Provider-Administered Revenue Model

YCANTH is a cantharidin 0.7% drug-device combination developed by Verrica Pharmaceuticals. It is supplied in a single-use applicator and applied by a trained professional every three weeks as needed, for up to four sessions. Cantharidin produces a localized blistering response, while the provider-controlled model supports precise application, reaction monitoring, and medical-benefit billing.

In two pivotal studies, complete clearance by Day 84 reached 46% with YCANTH compared with 18% for vehicle in one trial and 54% compared with 13% in the second. These results established an FDA-reviewed alternative to compounded cantharidin preparations.

Verrica reported YCANTH net product revenue of USD 15.3 million in 2025, up 130% from USD 6.6 million in 2024. Dispensed applicators rose 99% to 51,296 from 25,773. Within the combined USD 31.5 million in 2025 net product revenue reported for YCANTH and ZELSUVMI, YCANTH represented approximately 48.6%.

First-quarter 2026 U.S. YCANTH net product revenue reached USD 4.3 million, compared with USD 3.4 million a year earlier, while dispensed applicators increased 51.3% to 15,302. Cumulative dispensing exceeded 100,000 applicators after launch. These figures reflect growing utilization, although one patient may require multiple applicators or sessions.

YCANTH’s commercial growth depends on trained-provider participation, office inventory, claims processing, repeat treatment completion, and whether practice economics support product stocking and administration.

The 2025 result also marked a clear acceleration from the USD 4.7 million recorded in 2023 and USD 6.6 million in 2024. Over the two years from 2023 to 2025, YCANTH net product revenue increased at an implied CAGR of approximately 80.4%, reflecting the early scale-up phase of a newly launched provider-administered therapy rather than a mature long-term growth rate.

 

ZELSUVMI Moves Prescription Treatment into the Home

ZELSUVMI, or berdazimer topical gel 10.3%, is the first FDA-approved molluscum contagiosum therapy designed for at-home use. It is approved for adults and children aged one year and older and is applied once daily for up to twelve weeks. The product releases nitric oxide when its gel components are combined, while its main commercial distinction is avoiding repeated provider applications.

In two pivotal studies, complete clearance at Week 12 reached 32.4% with ZELSUVMI compared with 19.7% for vehicle in one study and 30.0% compared with 20.3% in the second. Application-site pain occurred in 18.7% of treated participants compared with 4.9% receiving vehicle.

Pelthos launched ZELSUVMI in July 2025 and reported USD 16.2 million in net product revenue for the year, representing six months of commercial activity. That placed ZELSUVMI at approximately 51.4% of the combined 2025 net product revenue reported for the two FDA-approved products, slightly above YCANTH despite its mid-year launch.

Prescribed units rose from 2,716 in the third quarter of 2025 to 6,232 in the fourth quarter, a sequential increase of approximately 129%. Prescriber count increased from 1,169 to 2,174, or about 86%, while total prescribed units reached 8,948 across the two quarters.

First-quarter 2026 ZELSUVMI net product revenue reached USD 10.7 million, up approximately 17% from USD 9.1 million in the fourth quarter of 2025. Across the two approved products, ZELSUVMI represented about 71.3% of their combined USD 15.0 million first-quarter 2026 net product revenue, while YCANTH represented 28.7%. This revenue mix reflects ZELSUVMI’s pharmacy distribution and wholesale launch buildout rather than a direct patient-share comparison.

The rapid shift in the branded revenue mix also reflects different launch mechanics. Pharmacy wholesalers can build inventory ahead of patient dispensing, while YCANTH revenue is more closely linked to applicators delivered through provider and clinic channels. Prescription units, dispensed units, and net product revenue should therefore be assessed together when comparing commercial momentum.

 

Reimbursement Determines Which Patients Receive Branded Therapy

Insurance access is critical because observation, inexpensive topicals, and established procedures remain available. CMS established the permanent HCPCS code J7354 for one YCANTH applicator, effective April 1, 2024, creating a standardized billing pathway for provider-administered treatment. Aetna considers YCANTH medically necessary for eligible patients aged two years and older, subject to treatment criteria and a maximum of four sessions per infection.

Verrica reported that approximately 250 million lives were eligible to receive YCANTH with insurance coverage by early 2026. This broad medical-benefit access supports the clinic-administered segment but still requires provider enrolment, product stocking, and successful claims.

ZELSUVMI depends more heavily on pharmacy formularies, copay assistance, prior authorization, retail availability, and prescription fulfilment. Pelthos secured a pharmacy-benefit-manager agreement covering more than 20 million lives. Its February 2026 investor data indicated 99% commercial coverage and 59% Medicaid coverage, while commercial, cash, and assistance programmes accounted for 74% of prescriptions, Medicaid for 26%, and Medicare for less than 1%.

The products therefore compete through different access structures. YCANTH must fit within medical-practice economics, while ZELSUVMI must convert prescriptions into dispensed and completed home treatment.

 

Pediatric Prescribers Control the Largest Commercial Opportunity

Children form the largest clinically relevant patient segment, making pediatric dermatologists, general dermatologists, pediatricians, nurse practitioners, and physician assistants the most important prescriber audiences. Dermatology practices remain central for extensive, facial, persistent, treatment-resistant, or diagnostically uncertain cases.

Pediatric and primary-care settings offer access to a larger volume of routine cases and are particularly important for ZELSUVMI because home therapy can be prescribed without maintaining office inventory. The adult market is smaller and more fragmented, with demand arising from genital transmission, contact sports, immunosuppression, and persistent lesions.

Pediatric treatment is expected to remain the leading patient segment, while adult and immunocompromised populations provide smaller but clinically significant opportunities.

Prescriber expansion is a central volume driver because many children are first seen in primary care rather than specialist dermatology. YCANTH benefits when pediatric and dermatology practices are equipped to administer and bill for treatment, while ZELSUVMI can reach practices that prefer to prescribe a home therapy without handling inventory.

 

North America Leads, While Japan Opens International Revenue

North America leads the commercial transition because both approved prescription therapies have entered the U.S. market and reimbursement pathways are established across medical and pharmacy benefits. The region also has concentrated dermatology networks and developed pediatric prescribing channels.

Japan became the first market outside the United States to launch the approved cantharidin product. Torii Pharmaceutical launched YCANTH on February 9, 2026, for molluscum contagiosum. Verrica reported USD 0.7 million in first-quarter 2026 license and collaboration revenue, primarily from commercial supply for the Japanese launch. This represented about 14% of Verrica’s combined USD 5.0 million in product and collaboration revenue for the quarter.

Europe and other regions continue to rely mainly on observation, cryotherapy, curettage, compounded preparations, and off-label topical therapies. Their future share will depend on regulatory submissions, pricing, reimbursement, pediatric treatment practices, and regional commercialization partnerships.

 

A Narrow Pipeline Raises the Value of Commercial Execution

The identifiable late-stage molluscum contagiosum pipeline remains limited. Near-term competition is therefore more likely to centre on expanding YCANTH and ZELSUVMI use than on frequent new product approvals.

VP-315, also known as ruxotemitide and formerly LTX-315, is not a molluscum contagiosum pipeline therapy; Verrica is developing the intralesional peptide for dermatologic oncology. Imiquimod is also better viewed as a legacy off-label comparator because its pediatric efficacy is limited.

Verrica must expand provider participation, reimbursement success, treatment completion, and international licensing. Pelthos must widen pharmacy coverage, improve prescription fulfilment, support caregiver adherence, and increase awareness among pediatric and primary-care prescribers.

 

Market Segmentation

By treatment, the market includes FDA-approved prescription therapies, physical removal procedures, off-label topical agents, and supportive or immune-directed approaches. Prescription therapies are the most commercially visible segment, with 2025 reported net product revenue split approximately 51.4% for home-administered ZELSUVMI and 48.6% for provider-administered YCANTH within the two-product branded market.

By administration setting, the market divides into healthcare-provider treatment and home-based treatment. The first-quarter 2026 revenue mix shifted toward home treatment, with ZELSUVMI accounting for approximately 71.3% of combined reported product revenue and YCANTH for 28.7%.

By patient group, the market includes pediatric patients, adults, and immunocompromised patients, with pediatric patients remaining the leading segment. By distribution channel, it includes dermatology and pediatric clinics, hospital outpatient departments, retail pharmacies, mail-order pharmacies, and patient-support services.

 

Molluscum Contagiosum Treatment Market Report Coverage Table

 

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.72 Million
Revenue Forecast in 2032	USD 1.32 Million
Overall Growth Rate	CAGR of 9.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Administration Setting, By Patient Group, By Distribution Channel, By Geography
By Treatment Type	FDA-Approved Prescription Therapies, Physical Removal Procedures, Off-Label Topical Therapies, Supportive and Immune-Directed Treatments
By Administration Setting	Healthcare Provider-Administered Treatment, Home-Based Treatment
By Patient Group	Pediatric Patients, Adults, Immunocompromised Patients
By Distribution Channel	Dermatology and Pediatric Clinics, Hospital Outpatient Departments, Retail Pharmacies, Mail-Order Pharmacies, Patient-Support Services
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising pediatric molluscum burden, FDA-approved prescription therapy adoption, increasing demand for faster lesion clearance, expansion of dermatology and pediatric treatment pathways, growing preference for standardized at-home and provider-administered treatment options
Customization Option	Available upon request